logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Repros Jumps on Positive Drug Trials

By  +Follow September 17, 2013 8:01AM
Share:
Tickers Mentioned:

Shares in Texas pharma Repros Therapeutics, Inc. (RPRX) gapped up over 30 percent in early morning trading before settling into gains of just over 10 percent on heavy volume as the day wore on. The spike, driven by positive topline results from the most recent study on its drug Androxal® reported after close on Monday, pushed Repros stock to a new 52-week high.

Positive results for Androxal

Androxal is being developed for men of reproductive age with low testosterone due to secondary hypogonadism, which is also associated with obesity and could be among the most common causes of low testosterone. Repros reported that Andorxal met both co-primary endpoints in its second pivotal study, with 81 percent of subjects using the drug experiencing normalized testosterone and no 24-hour average testosterone levels outside of normal ranges. Androxal, which is in a class similar to Sanofi’s (SNY) Clomid®, could receive a strong share of the testosterone replacement therapy (TRT) market because it could also help preserve male fertility while being administered orally, making it significantly more convenient than testosterone replacement injections.  

Possible Sale

Brean Capital initiated coverage of Repros in July of this year, calling it a buy and setting a price target of $32. At the time, analyst Jonathan Aschoff said “Its lead compound Androxal is being evaluated in a Phase 3 program for secondary hypogonadism with results in 4Q13 and 2Q14, which in our view would be key investment catalysts, and we project Androxal launch in mid-2015.” Now, Brean is citing these positive results as a reason for optimism, as well as reports that management may have interest in selling the company. Brean estimated the sell-price potentially reaching $40 a share, in the event that the sale goes down.

In addition to Andorxal, Repros currently has female reproductive drug Proellex® in the pipeline, intended for use in uterine fibroids and endometriosis. “The vaginal formulation of Proellex (Proellex-V) will enter Phase 2b in 2H13 for uterine fibroids with an NDA submission expected in 2016. All compounds are protected by U.S. patents," said Aschoff in July.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for RPRX
US_proptrader
2 Sep 14 08:59:05
$AMBA $RPRX $UEPS $WUBA autocharts @ http://t.co/hj7PGeTQk3
US_proptrader
2 Sep 14 08:42:16
$ARWR $CODE $DATA $DSKY $FEYE $FUEL $RPRX $TSLA $WUBA autocharts @ http://t.co/hj7PGeTQk3
Sleek Money
2 Sep 14 04:38:44
Repros Therapeutics’s Positive Rating Reiterated at Ascendiant Capital Markets $RPRX http://t.co/R9CwU2EWCy
Market Updates
2 Sep 14 03:45:00
$RPRX: REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure http://t.co/E1vtm6FikQ http://t.co/fVJBsayoGa
12Stocks.com
2 Sep 14 03:04:47
Weekly SmallCap #Stocks Trend $RSH $ENZN $RPRX $CLUB $EXPR $ARO $ISIS $RALY $OMER $BDSI $GDP $ATRS more@ http://t.co/Giravo3fg9
12Stocks.com
2 Sep 14 03:04:12
Weekly Smallcap #Stocks Performance $RSH $ITMN $ENZN $RPRX $CLUB $FOLD $EXPR $ARO $ISIS $ACHN $RALY more@ http://t.co/Giravo3fg9
Freefdawatchlist
1 Sep 14 13:45:44
http://t.co/dMivqbswlm Overbought Stock: $CSIQ, $SGMS, $BITA, $TUBE, $TRUE, $RPRX, $ACHN, $X, $DGLY http://t.co/HNJ4MHwkVs
Shiraz Lakhi
1 Sep 14 09:54:19
Breaking: Top HEALTHCARE #stocks in-play on STRONG-VOLUME-BREAKOUT $UTHR $AEZS $VEEV $ENZN $RPRX +more (click "View") http://t.co/VkowAGwOHx
VisualStock Resource
1 Sep 14 09:48:24
$VEEV up 20.07% today! Check out this trade http://t.co/zrPbQ96ROz I made 14% on $RPRX JOIN US LIVE: http://t.co/GvCHH5QLUb
Business Headlines
1 Sep 14 08:45:16
$RPRX: Why Repros Therapeutics (RPRX) Stock Is Surging Today http://t.co/ruv6qfGPDn http://t.co/ZEXzxFEupb
joshwin
1 Sep 14 08:01:55
$RPRX PT lifted to 30 at BofA http://t.co/ulSlJsruTB
WKRB News
1 Sep 14 06:41:28
Repros Therapeutics’s “Positive” Rating Reiterated at Ascendiant Capital Markets $RPRX http://t.co/ZwQ9cQFm4h
12Stocks.com
1 Sep 14 03:04:00
Weekly SmallCap #Stocks Trend $RSH $ENZN $RPRX $CLUB $EXPR $ARO $ISIS $RALY $OMER $BDSI $GDP $ATRS more@ http://t.co/Giravo3fg9
12Stocks.com
1 Sep 14 03:03:40
Weekly Smallcap #Stocks Performance $RSH $ITMN $ENZN $RPRX $CLUB $FOLD $EXPR $ARO $ISIS $ACHN $RALY more@ http://t.co/Giravo3fg9
OTPicks.com
1 Sep 14 01:10:17
http://t.co/rruxxRYVwc $heff: $RPRX..Repros Therapeutics PT Lifted to $30 at BofA/Merr http://t.co/Tx5nFz6mt9 http://t.co/rruxxRYVwc
Financial Headlines
31 Aug 14 21:44:59
$RPRX: Why Repros Therapeutics (RPRX) Stock Is Surging Today http://t.co/S8cLTrR302 http://t.co/RosoBxRKeZ
On Time Picks
31 Aug 14 20:23:52
iwfal: $RPRX - Then, there is the absence of: iwfal http://t.co/8a4evlH5d9
On Time Picks
31 Aug 14 13:16:21
hptaxis: $RPRX "PumP" Podolski PR: hptaxis http://t.co/xmJMX7lQDl
Roy Friedman
31 Aug 14 13:00:57
.@ianestepan Another opinion on the misinformation from $RPRX: http://t.co/HKy0IgBm9S
Stock News Headlines
31 Aug 14 09:44:55
$RPRX: Options Radar: Twitter Inc, RadioShack, and Repros Therapeutics Inc http://t.co/EvMtB4o10H http://t.co/3SiEbHOcs6
Stocks Pastor
30 Aug 14 05:44:59
$RPRX target raised to $25
Stock News Guru
30 Aug 14 03:44:53
$RPRX: Morning Movers to Watch - Repros Therapeutics Inc (RPRX), RadioShack ... http://t.co/UCuj3pjVEy http://t.co/iM2Pp1WChD
12Stocks.com
30 Aug 14 03:04:35
Weekly SmallCap #Stocks Trend $RSH $ENZN $RPRX $CLUB $EXPR $ARO $ISIS $RALY $OMER $BDSI $GDP $ATRS more@ http://t.co/Giravo3fg9
12Stocks.com
30 Aug 14 03:04:14
Weekly Smallcap #Stocks Performance $RSH $ITMN $ENZN $RPRX $CLUB $FOLD $EXPR $ARO $ISIS $ACHN $RALY more@ http://t.co/Giravo3fg9
joshwin
29 Aug 14 18:13:51
RT @MaisaCorp: $RPRX big boys are now officially controlling $RPRX. They are accumulating shares! $22+
Arab_Zanger
29 Aug 14 15:02:58
RT @bo3bo32: $AAPL $GOOG $PCLN $NFLX $FB #OPTIONS $TSLA $TWTR $RPRX BOOOOOOOOOOOOOOOOOOOM http://t.co/M2kkptD12W
Arab_Zanger
29 Aug 14 15:02:51
RT @bo3bo32: $AAPL $GOOG $PCLN $NFLX $FB #OPTIONS $TSLA $TWTR $RPRX NOW 7.30$ 150%
Eunice Thompson
29 Aug 14 13:56:31
Another awesome day with stockspastor. $DGLY, $GS, $RPRX, $ISNS, $TKMR. He makes making $$$ so easy. You have to be smart to make it here.
TalkMarkets
29 Aug 14 13:52:57
Laidlaw's Yale Jen: #Biotech 101 For Buyers And Sellers $GSK $ISIS $RPRX $BIIB $ADMA $MSTX $PFE $GLYC http://t.co/dyKwIE1oik
Success is my story
29 Aug 14 13:29:43
http://t.co/qGyCpCoCXX Verified $253.92 profit in $RPRX nice profit
Yu Zhu
29 Aug 14 12:46:09
RT @pick1998_2: biotech finish Aug strong. $TKMR, $BLUE, $FOLD, $RPRX ... up we go.
US_proptrader
29 Aug 14 12:45:15
$ACHN $EXEL $EXPR $LEJU $OREX $RPRX $SRPT $TKMR $TUBE autocharts @ http://t.co/hj7PGeTQk3
Business Updates
29 Aug 14 12:45:06
$RPRX: REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure http://t.co/iUqGpf5kjx http://t.co/E1aFVyr1WZ
Nick zheng
29 Aug 14 12:35:50
biotech finish Aug strong. $TKMR, $BLUE, $FOLD, $RPRX ... up we go.
Stocks Pastor
29 Aug 14 12:14:14
stick with what works. $DGLY working. $RPRX working. we have been nailing it since open.
Stocks Pastor
29 Aug 14 11:55:11
All watch list stocks rock today if you caught the bottom: $SEAS, $FEYE, $KITE, $DGLY, $RPRX, etc...
US_proptrader
29 Aug 14 11:54:02
$BSMX $EXEL $RPRX $SRPT $TKMR autocharts @ http://t.co/hj7PGeTQk3
Shiraz Lakhi
29 Aug 14 11:02:44
Breaking: Top SMALLCAP #stocks in-play on STRONG-VOLUME-BREAKOUT $UEPS $ANFI $RPRX $VMEM $GES +more (click "View") http://t.co/G9HycZZMSP
US_proptrader
29 Aug 14 10:48:04
$CLF $CPRX $EXPR $HCLP $RPRX $TUBE autocharts @ http://t.co/hj7PGeTQk3
Financial News
29 Aug 14 10:45:07
$RPRX: Repros Therapeutics reaches enrollment goal in second Androxal study http://t.co/ZN60w4udse http://t.co/yORjr8iKEX
TipRanks
29 Aug 14 10:13:11
0-star analyst Keay Nakae from Ascendiant reiterated a BUY rating on $RPRX. Keay has a 33.3% success rate http://t.co/Qj9qS2DgLC
US_proptrader
29 Aug 14 09:44:03
$CLF $GLNG $MSTX $RPRX $SID $SWIR autocharts @ http://t.co/hj7PGeTQk3
MAISA
29 Aug 14 09:43:53
$RPRX big boys are now officially controlling $RPRX. They are accumulating shares! $22+
nobullshytrader
29 Aug 14 09:39:11
c everyone tuezday were long $FWM $VCRA short $TSLA $GILD $SPY $HD $LNKD $JRJC $ARUN $TASR my parter took shorts in $KSS $RPRX $ISIS also
Kim Smith
29 Aug 14 09:29:13
RT @pick1998_2: $RPRX data say everything. The stock will be a good buy for a long term. Market cap is low for a new paradigm treatment of …
US_proptrader
29 Aug 14 09:25:09
$BVN $CODE $GOMO $RFMD $RPRX $SWIR $TKMR $TQNT $TUBE autocharts @ http://t.co/hj7PGeTQk3
Vaulty Boy
29 Aug 14 08:49:20
$RPRX low vol... $22 is the line
Stock News Headlines
29 Aug 14 08:45:06
$RPRX: Repros Therapeutics (RPRX) Reports Positive Top Line Data in Androxal Studies http://t.co/5IftmebGeh http://t.co/GHu9lE225i
Kim Smith
29 Aug 14 08:33:01
RT @pick1998_2: $RPRX most likely to keep moving up to second phase III (study 304) data in Oct. Lots of short to cover. Buy.
Vaulty Boy
29 Aug 14 08:26:41
$RPRX testing the short term trend now! waiting for confirmation for an entry
				
				
By  +Follow September 17, 2013 8:01AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.